Recormon Gets New Indication In EU
Boehringer Mannheim has been granted a positive opinion from theEuropean Medicines Evaluation Agency to market its erythropoietin product Recormon (epoetin beta) for a new indication, the treatment of platinum-induced anemia in cancer patients with solid tumors. It is currently indicated to treat renal failure-associated anemia and for the prevention of anemia in premature babies.
Boehringer Mannheim has also been granted approval for an improved formulation of the peptide, called NeoRecormon, in two new presentations; RecoPen, a self-injector, and Multidose, which can be used to dose multiple patients from a single vial, with potential cost savings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze